SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes
Event: ESC Congress 2019
Topic: Antidiabetic Pharmacotherapy
Session: New frontiers: SGLT2 inhibitors in cardiorenal disease
ESC 365 is supported by
